Clinical Trials › NCT03846219
Active, Not RecruitingPhase 2
MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
Sponsored by Immunic AG
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 210
Target enrollment
Jan 2019
Start date
Dec 2029
Expected completion
Interventions / Treatments
IMU-838 (30 mg/day)IMU-838 (45 mg/day)PlaceboIMU-838 (10 mg/day)
Conditions studied
Relapsing-Remitting Multiple Sclerosis (RRMS)
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 2 trials
Browse all Phase 2 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.